These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 24487084)

  • 1. Oxcabazepine (®Trileptal) in Anti-epileptic Polytherapy.
    Jensen PK
    Behav Neurol; 1990; 3(1):35-9. PubMed ID: 24487084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?
    Schmidt D; Elger CE
    Epilepsy Behav; 2004 Oct; 5(5):627-35. PubMed ID: 15380112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxcarbazepine in monotherapy.
    Dam M
    Behav Neurol; 1990; 3(1):31-4. PubMed ID: 24487083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxcarbazepine: current status and clinical applications.
    Schachter SC
    Expert Opin Investig Drugs; 1999 Jul; 8(7):1103-12. PubMed ID: 15992110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
    Ahmad A; Garnett WR
    Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oxcarbazepine in the treatment of epilepsy. A review and update].
    Horga de la Parte JF; Horga A
    Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Factors Impacting the Efficacy of Single or Combination Therapies of Valproic Acid, Carbamazepine, and Oxcarbazepine: A Longitudinal Observation Study.
    Peng Q; Ma M; Gu X; Hu Y; Zhou B
    Front Pharmacol; 2021; 12():641512. PubMed ID: 34017250
    [No Abstract]   [Full Text] [Related]  

  • 8. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures.
    Zheng T; Clarke AL; Morris MJ; Reid CA; Petrou S; O'Brien TJ
    Epilepsia; 2009 Jan; 50(1):83-7. PubMed ID: 18717705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.
    Gelisse P; Genton P; Kuate C; Pesenti A; Baldy-Moulinier M; Crespel A
    Epilepsia; 2004 Oct; 45(10):1282-6. PubMed ID: 15461683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
    Flesch G; Czendlik C; Renard D; Lloyd P
    Drug Metab Dispos; 2011 Jun; 39(6):1103-10. PubMed ID: 21389120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
    Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
    Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
    Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
    Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
    Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine.
    Albani F; Baruzzi A;
    Neurol Sci; 2006 Jul; 27(3):173-5. PubMed ID: 16897629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
    Mintzer S; Boppana P; Toguri J; DeSantis A
    Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Anti-epileptic Drugs and their Clinical Significance.
    Johannessen SI
    Behav Neurol; 1990; 3(1):1-11. PubMed ID: 24487080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxcarbazepine extended-release formulation in epilepsy.
    Steinhoff BJ
    Expert Rev Clin Pharmacol; 2009 Mar; 2(2):155-62. PubMed ID: 24410646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine.
    Clemens B; Ménes A; Nagy Z
    Acta Neurol Scand; 2004 May; 109(5):324-9. PubMed ID: 15080858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR
    Faison S; Gomeni R; Mendes S; O'Neal W; Schwabe S; Nasser A
    Clin Pharmacol; 2020; 12():135-147. PubMed ID: 33061671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.